<DOC>
	<DOCNO>NCT02668185</DOCNO>
	<brief_summary>Placebo-controlled , double-blinded , cross-over clinical trial new investigational product</brief_summary>
	<brief_title>Neuropeptide Treatment Hot Flushes During Menopause</brief_title>
	<detailed_description>Double-blinded , placebo-controlled , 2-way crossover study 30 menopausal woman untreated hot flush treat neurokinin 3 receptor ( NK3R ) antagonist Aims : To investigate whether NK3R antagonist reduce menopausal flush Treatment : 4 week administration active drug placebo random order</detailed_description>
	<mesh_term>Flushing</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>Menopausal woman ( ≥12 month since last menstrual period bilateral oophorectomy follicle stimulate hormone ( FSH ) level ≥20 milliinternational units/millilitre ( mIU/mL ) estradiol level &lt; 190pmol/l absence reliable menstrual marker ( hysterectomy ovarian preservation endometrial ablation ) ) age 4062 year &gt; 7 hot flushes/day report severe bothersome treatment menopausal symptom precede 8 week . 1 . Significant illness , judge Investigator , within 2 week first study visit . 2 . Volunteer clinical , laboratory , electrocardiogram ( ECG ) evidence uncontrolled hypertension ( define systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥100 mmHg ) ; uncontrolled diabetes ; significant pulmonary , renal , hepatic , endocrine , systemic disease opinion Investigator . 3 . Participant history Gilbert 's syndrome , infectious hepatitis , significant hepatic disease ( e.g . chronic hepatitis , cirrhosis , autoimmune hepatitis , primary sclerosing cholangitis , nonalcoholic steatohepatitis , hereditary liver disease ) opinion Investigator . 4 . Participant history surgery opinion investigator could cause malabsorption ( e.g . gastric small intestinal surgery gastric bypass surgery banding ) , patient disease cause malabsorption . 5 . Clinically significant abnormal ECG and/or abnormality ECG screen judged Investigator . 6 . A marked prolongation QT/corrected QT ( QTc ) interval ( e.g . repeat demonstration QTc interval &gt; 450 m ) . 7 . Confirmed history ischaemic heart disease . 8 . Past ( within 1 year enrollment ) present alcohol substance abuse 9 . Has receive another new chemical entity ( define compound approve marketing ) participate clinical study include drug treatment within least 3 month first administration AZD4901 study . The period exclusion begin 3 month final dose . ( Note : patient consent screened , randomise previous study exclude . ) 10 . Participant history neoplastic disease within 5 year prior sign inform consent currently ongoing treatment prevent cancer recurrence . 11 . Involvement plan and/or conduct study ( applies AstraZeneca employee close relative and/or staff study site directly involve study , regardless role accordance internal procedure ) 12 . Inability understand cooperate requirement study 13 . Participant legally mentally incapacitated 14 . Participant significant psychiatric disease treatment psychiatric disease e.g . selective serotonin reuptake inhibitor ( SSRIs ) opinion Investigator may influence result study . 15 . Participant abnormal screen laboratory value per guideline list clinically significant , unexplained laboratory abnormality accord Investigator : Aspartate aminotransferase ( AST ) &gt; 1.5 time upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) &gt; 1.5 time ULN Total bilirubin &gt; 1.5 time ULN Serum creatinine &gt; 2.0 time ULN 16 . Clinically relevant disease abnormality ( past present ) , opinion Investigator , may either put patient risk participate study may influence result study patient 's ability participate study . 17 . Participant history hyperthyroidism hypothyroidism abnormal screen thyroid test , judge Investigator . Patients hypothyroidism stable treatment normal thyroid function test may include study opinion Investigator influence result study . 18 . Participant seizure , patient history seizure condition increase risk seizure . 19 . Participant history hypersensitivity 2 chemical class drug , include prescription overthecounter medication . 20 . Participant take potent moderate CYP3A4 CYP2C9 inhibitor , potent moderate CYP3A4 CYP2C9 inducer , hormonal contraceptive , antiandrogenic drug , medication specify time frame</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>